Asthma

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

The HCPLive editorial team previews late-breaking abstracts across COPD, asthma, IPF, PAH, and AATD ahead of ERS Congress 2026 in Barcelona.

Academic pulmonologists from Mass General, Duke, and Cleveland Clinic discuss biologic selection, mucus plugging, and more.

Pulmonologists weigh in on biologic selection, mepolizumab tachyphylaxis, COPD payer barriers, and why asthma outcomes far outpace COPD in real-world practice.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

June 2026 pulmonology news includes conversations with experts at the ATS and APAPP conferences, and cytisinicline's CRL.

Heather O'Connell, PA-C, makes the case that missing rhinitis, nasal polyps, or NSAID sensitivity is costing patients exacerbations and hospitalizations.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

Octavio Galindo, MD, discusses findings from a prospective Spanish cohort (SENDO) linking high UPF intake to asthma incidence in school-age children.

Jose Arias Jr., MD, discusses GINA 2025 criteria, ICS initiation, device education, and distinguishing viral wheezing from early asthma in children under 5 years.

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

Payel Gupta, MD, discusses how IgE, FeNO, and type 2 comorbidities inform biologic choice and when a lack of response warrants switching agents.

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

At ATS 2026, Couillard discussed a win ratio analysis showing dupilumab significantly improved remission outcomes, particularly among patients with elevated eosinophils and FeNO.

Brittany Duchene, MD, found that depressive symptoms were associated with twice the odds of poorly controlled asthma.

This interview highlights phase 3 findings from the SUNRISE study regarding tezepelumab and oral corticosteroid (OCS) reduction in patients with severe, OCS-dependent asthma.

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.